April 16, 2004
Gilead Sciences to Release First Quarter 2004 Financial Results on Thursday, April 22, 2004; Conference Call and Webcast to Follow
FOSTER CITY, Calif.--(BUSINESS WIRE)--April 16, 2004--Gilead Sciences, Inc. (Nasdaq:GILD) announced today that its first quarter 2004 financial results will be released on Thursday, April 22, 2004, at 4:00 p.m. Eastern Time. At 4:30 p.m. Eastern Time Gilead will webcast a conference call live on the company's internet site. The call will be led by John Martin, PhD, President and Chief Executive Officer, Mark Perry, Executive Vice President of Operations, and John Milligan, PhD, Executive Vice President and Chief Financial Officer. They will discuss the Company's first quarter results for 2004, provide an overview of the Company and an outlook for the remainder of 2004.
To access the webcast via the internet, log on to www.gilead.com. Please connect to the company's website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be needed to hear the webcast. Alternatively, please call 1-800-237-9752 (U.S.) or 1-617-847-8706 (international) and dial the participant passcode 94778515 to access the call. Telephone replay is available approximately two hours after the call through 6:30 p.m. Eastern Time, April 25, 2004. To access, please call 1-888-286-8010 (U.S.) or 1-617-801-6888 (international) and dial the participant passcode 61661635. The webcast will be archived on www.gilead.com for one year.
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes therapeutics to advance the care of patients suffering from life-threatening diseases worldwide. The company has six marketed products and focuses its research and clinical programs on anti-infectives. Headquartered in Foster City, CA, Gilead has operations in the United States, Europe and Australia.
For more information on Gilead Sciences, please visit the company's web site at www.gilead.com or call the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235).
CONTACT: Gilead Sciences, Inc.
Susan Hubbard, 650-522-5715 (Investor Relations)
SOURCE: Gilead Sciences, Inc.